MET-097i: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข2 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Storage conditions not publicly disclosed. Refrigerated storage (2-8 degrees C) is expected for the peptide-oligomer conjugate.
Protocol Quick-Reference
Obesity and overweight with comorbidities
Dosing
Amount
9.6 mg (monthly target dose)
Frequency
Once monthly
Duration
28 weeks (Phase 2b)
Administration
Route
SCSchedule
Once monthly (after initial weekly transition)
Timing
Weekly-to-monthly transition protocol used in clinical trials; initial weekly dosing before transitioning to once-monthly injection
Cycle
Duration
Ongoing
Repeatable
Yes
โ๏ธ Suggested Bloodwork (4 tests)
Fasting glucose and HbA1c
When: Baseline
Why: Baseline glycemic status
Lipid panel
When: Baseline
Why: Baseline cardiovascular risk markers
Fasting glucose and HbA1c
When: 12 weeks
Why: Monitor glycemic changes
Lipid panel
When: 28 weeks
Why: Assess metabolic improvements
๐ก Key Considerations
- โInvestigational drug: not approved by any regulatory authority
- โContains biased GLP-1 agonism which may reduce GI side effects compared to unbiased agonists
- โClinical validation of direct monthly dosing protocol is pending Phase 3 trials
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Weight Management (VESPER-3 Phase 2b) | Weekly-to-monthly transition protocol: initial weekly dosing transitioning to once-monthly subcutaneous injection. Monthly 9.6 mg dose evaluated. | Once monthly subcutaneous injection (after transition) | 28 weeks (Phase 2b trial) | The weekly-to-monthly transition achieved 12.3% weight loss at 28 weeks. Pharmacokinetic modeling suggests 9.6 mg monthly could achieve approximately 16% weight loss with continued treatment. |
| Weight Management (Direct Monthly Dosing - Modeled) | 9.6 mg once monthly subcutaneous injection (from PK modeling). | Once monthly subcutaneous injection | Projected from modeling data | Direct monthly dosing protocol derived from pharmacokinetic modeling. Clinical validation in Phase 3 trials pending. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
Reconstitution details not publicly disclosed. MET-097i is administered as a once-monthly subcutaneous injection.
Recommended Injection Sites
- โAbdomen
- โThigh
- โUpper arm
๐งStorage Requirements
Storage conditions not publicly disclosed. Refrigerated storage (2-8 degrees C) is expected for the peptide-oligomer conjugate.
Community Dosing Protocols
Compare these clinical doses with what community members report using.
0View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Investigational Status#
MET-097i is an investigational drug not approved by any regulatory authority. All dosing information is derived from clinical trials and pharmacokinetic modeling.
VESPER-3 Phase 2b Dosing#
The VESPER-3 trial used a weekly-to-monthly transition protocol. Participants started with weekly injections and then transitioned to once-monthly dosing.
| Protocol | Weight Loss | Duration |
|---|---|---|
| Weekly-to-monthly transition | 12.3% | 28 weeks |
| Monthly 9.6 mg (modeled) | ~16% projected | Continued treatment |
Monthly Dosing Advantage#
The ability to dose once monthly is a key differentiator for MET-097i. This reduces injection burden from 52 to 12 injections per year compared to weekly GLP-1 agonists.
| Dosing Frequency | Injections Per Year | Examples |
|---|---|---|
| Daily | 365 | Liraglutide |
| Weekly | 52 | Semaglutide, tirzepatide |
| Monthly | 12 | MET-097i (target) |
Administration#
MET-097i is administered as a subcutaneous injection. The transition from weekly to monthly dosing allows initial dose optimization before moving to the more convenient monthly regimen.
Dosing Context#
MET-097i belongs to the Metabolic category of research peptides. Dosing protocols for MET-097i are derived from available clinical trial data. These protocols are provided for research reference only and do not constitute medical advice. Actual dosing decisions should be made by qualified healthcare providers based on individual patient factors.
Research Protocols#
The following dosing protocols have been documented in clinical research for MET-097i:
Weight Management (VESPER-3 Phase 2b)#
Dose: Weekly-to-monthly transition protocol: initial weekly dosing transitioning to once-monthly subcutaneous injection. Monthly 9.6 mg dose evaluated.
Frequency: Once monthly subcutaneous injection (after transition)
Duration: 28 weeks (Phase 2b trial)
The weekly-to-monthly transition achieved 12.3% weight loss at 28 weeks. Pharmacokinetic modeling suggests 9.6 mg monthly could achieve approximately 16% weight loss with continued treatment.
Weight Management (Direct Monthly Dosing - Modeled)#
Dose: 9.6 mg once monthly subcutaneous injection (from PK modeling).
Frequency: Once monthly subcutaneous injection
Duration: Projected from modeling data
Direct monthly dosing protocol derived from pharmacokinetic modeling. Clinical validation in Phase 3 trials pending.
Reconstitution and Preparation#
Reconstitution details not publicly disclosed. MET-097i is administered as a once-monthly subcutaneous injection.
Injection Sites#
Recommended injection sites for MET-097i include:
- Abdomen
- Thigh
- Upper arm
Site rotation is recommended to minimize local tissue reactions and ensure consistent absorption.
Storage Requirements#
Storage conditions not publicly disclosed. Refrigerated storage (2-8 degrees C) is expected for the peptide-oligomer conjugate.
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About MET-097i
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.